Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates
The coformulation of the nucleos(t)ide analogs (NA) tenofovir (TFV) disoproxil fumarate (TDF) and emtricitabine (FTC) is approved for HIV-infection treatment and prevention. Plasma TFV and FTC undergo complicated hybrid processes to form, accumulate, and retain as their active intracellular anabolit...
Saved in:
| Published in | PloS one Vol. 11; no. 11; p. e0165505 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
10.11.2016
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The coformulation of the nucleos(t)ide analogs (NA) tenofovir (TFV) disoproxil fumarate (TDF) and emtricitabine (FTC) is approved for HIV-infection treatment and prevention. Plasma TFV and FTC undergo complicated hybrid processes to form, accumulate, and retain as their active intracellular anabolites: TFV-diphosphate (TFV-DP) and FTC-triphosphate (FTC-TP). Such complexities manifest in nonlinear intracellular pharmacokinetics (PK). In target cells, TFV-DP/FTC-TP compete with endogenous deoxynucleoside triphosphates (dNTP) at the active site of HIV reverse transcriptase, underscoring the importance of analog:dNTP ratios for antiviral efficacy. However, NA such as TFV and FTC have the potential to disturb the dNTP pool, which could augment or reduce their efficacies. We conducted a pharmacokinetics-pharmacodynamics (PKPD) study among forty subjects receiving daily TDF/FTC (300 mg/200 mg) from the first-dose to pharmacological intracellular steady-state (30 days). TFV/FTC in plasma, TFV-DP/FTC-TP and dNTPs in peripheral blood mononuclear cells (PBMC) were quantified using validated LC/MS/MS methodologies. Concentration-time data were analyzed using nonlinear mixed effects modeling (NONMEM). Formations and the accumulation of intracellular TFV-DP/FTC-TP was driven by plasma TFV/FTC, which was described by a hybrid of first-order formation and saturation. An indirect response link model described the interplay between TFV-DP/FTC-TP and the dNTP pool change. The EC50 (interindividual variability, (%CV)) of TFV-DP and FTC-TP on the inhibition of deoxyadenosine triphosphate (dATP) and deoxycytidine triphosphate (dCTP) production were 1020 fmol/106 cells (130%) and 44.4 pmol/106 cells (82.5%), resulting in (90% prediction interval) 11% (0.45%, 53%) and 14% (2.6%, 35%) reductions. Model simulations of analog:dNTP molar ratios using IPERGAY dosing suggested that FTC significantly contributes to the protective effect of preexposure prophylaxis (PrEP). Simulation-based intracellular operational multiple dosing half-lives of TFV-DP and FTC-TP were 6.7 days and 33 hours. This model described the formation of intracellular TFV-DP/FTC-TP and the interaction with dNTPs, and can be used to simulate analog:dNTP time course for various dosing strategies. |
|---|---|
| AbstractList | The coformulation of the nucleos(t)ide analogs (NA) tenofovir (TFV) disoproxil fumarate (TDF) and emtricitabine (FTC) is approved for HIV-infection treatment and prevention. Plasma TFV and FTC undergo complicated hybrid processes to form, accumulate, and retain as their active intracellular anabolites: TFV-diphosphate (TFV-DP) and FTC-triphosphate (FTC-TP). Such complexities manifest in nonlinear intracellular pharmacokinetics (PK). In target cells, TFV-DP/FTC-TP compete with endogenous deoxynucleoside triphosphates (dNTP) at the active site of HIV reverse transcriptase, underscoring the importance of analog:dNTP ratios for antiviral efficacy. However, NA such as TFV and FTC have the potential to disturb the dNTP pool, which could augment or reduce their efficacies. We conducted a pharmacokinetics-pharmacodynamics (PKPD) study among forty subjects receiving daily TDF/FTC (300 mg/200 mg) from the first-dose to pharmacological intracellular steady-state (30 days). TFV/FTC in plasma, TFV-DP/FTC-TP and dNTPs in peripheral blood mononuclear cells (PBMC) were quantified using validated LC/MS/MS methodologies. Concentration-time data were analyzed using nonlinear mixed effects modeling (NONMEM). Formations and the accumulation of intracellular TFV-DP/FTC-TP was driven by plasma TFV/FTC, which was described by a hybrid of first-order formation and saturation. An indirect response link model described the interplay between TFV-DP/FTC-TP and the dNTP pool change. The
EC
50
(interindividual variability, (%CV)) of TFV-DP and FTC-TP on the inhibition of deoxyadenosine triphosphate (dATP) and deoxycytidine triphosphate (dCTP) production were 1020 fmol/10
6
cells (130%) and 44.4 pmol/10
6
cells (82.5%), resulting in (90% prediction interval) 11% (0.45%, 53%) and 14% (2.6%, 35%) reductions. Model simulations of analog:dNTP molar ratios using IPERGAY dosing suggested that FTC significantly contributes to the protective effect of preexposure prophylaxis (PrEP). Simulation-based intracellular operational multiple dosing half-lives of TFV-DP and FTC-TP were 6.7 days and 33 hours. This model described the formation of intracellular TFV-DP/FTC-TP and the interaction with dNTPs, and can be used to simulate analog:dNTP time course for various dosing strategies. The coformulation of the nucleos(t)ide analogs (NA) tenofovir (TFV) disoproxil fumarate (TDF) and emtricitabine (FTC) is approved for HIV-infection treatment and prevention. Plasma TFV and FTC undergo complicated hybrid processes to form, accumulate, and retain as their active intracellular anabolites: TFV-diphosphate (TFV-DP) and FTC-triphosphate (FTC-TP). Such complexities manifest in nonlinear intracellular pharmacokinetics (PK). In target cells, TFV-DP/FTC-TP compete with endogenous deoxynucleoside triphosphates (dNTP) at the active site of HIV reverse transcriptase, underscoring the importance of analog:dNTP ratios for antiviral efficacy. However, NA such as TFV and FTC have the potential to disturb the dNTP pool, which could augment or reduce their efficacies. We conducted a pharmacokinetics-pharmacodynamics (PKPD) study among forty subjects receiving daily TDF/FTC (300 mg/200 mg) from the first-dose to pharmacological intracellular steady-state (30 days). TFV/FTC in plasma, TFV-DP/FTC-TP and dNTPs in peripheral blood mononuclear cells (PBMC) were quantified using validated LC/MS/MS methodologies. Concentration-time data were analyzed using nonlinear mixed effects modeling (NONMEM). Formations and the accumulation of intracellular TFV-DP/FTC-TP was driven by plasma TFV/FTC, which was described by a hybrid of first-order formation and saturation. An indirect response link model described the interplay between TFV-DP/FTC-TP and the dNTP pool change. The EC50 (interindividual variability, (%CV)) of TFV-DP and FTC-TP on the inhibition of deoxyadenosine triphosphate (dATP) and deoxycytidine triphosphate (dCTP) production were 1020 fmol/106 cells (130%) and 44.4 pmol/106 cells (82.5%), resulting in (90% prediction interval) 11% (0.45%, 53%) and 14% (2.6%, 35%) reductions. Model simulations of analog:dNTP molar ratios using IPERGAY dosing suggested that FTC significantly contributes to the protective effect of preexposure prophylaxis (PrEP). Simulation-based intracellular operational multiple dosing half-lives of TFV-DP and FTC-TP were 6.7 days and 33 hours. This model described the formation of intracellular TFV-DP/FTC-TP and the interaction with dNTPs, and can be used to simulate analog:dNTP time course for various dosing strategies. The coformulation of the nucleos(t)ide analogs (NA) tenofovir (TFV) disoproxil fumarate (TDF) and emtricitabine (FTC) is approved for HIV-infection treatment and prevention. Plasma TFV and FTC undergo complicated hybrid processes to form, accumulate, and retain as their active intracellular anabolites: TFV-diphosphate (TFV-DP) and FTC-triphosphate (FTC-TP). Such complexities manifest in nonlinear intracellular pharmacokinetics (PK). In target cells, TFV-DP/FTC-TP compete with endogenous deoxynucleoside triphosphates (dNTP) at the active site of HIV reverse transcriptase, underscoring the importance of analog:dNTP ratios for antiviral efficacy. However, NA such as TFV and FTC have the potential to disturb the dNTP pool, which could augment or reduce their efficacies. We conducted a pharmacokinetics-pharmacodynamics (PKPD) study among forty subjects receiving daily TDF/FTC (300 mg/200 mg) from the first-dose to pharmacological intracellular steady-state (30 days). TFV/FTC in plasma, TFV-DP/FTC-TP and dNTPs in peripheral blood mononuclear cells (PBMC) were quantified using validated LC/MS/MS methodologies. Concentration-time data were analyzed using nonlinear mixed effects modeling (NONMEM). Formations and the accumulation of intracellular TFV-DP/FTC-TP was driven by plasma TFV/FTC, which was described by a hybrid of first-order formation and saturation. An indirect response link model described the interplay between TFV-DP/FTC-TP and the dNTP pool change. The EC50 (interindividual variability, (%CV)) of TFV-DP and FTC-TP on the inhibition of deoxyadenosine triphosphate (dATP) and deoxycytidine triphosphate (dCTP) production were 1020 fmol/106 cells (130%) and 44.4 pmol/106 cells (82.5%), resulting in (90% prediction interval) 11% (0.45%, 53%) and 14% (2.6%, 35%) reductions. Model simulations of analog:dNTP molar ratios using IPERGAY dosing suggested that FTC significantly contributes to the protective effect of preexposure prophylaxis (PrEP). Simulation-based intracellular operational multiple dosing half-lives of TFV-DP and FTC-TP were 6.7 days and 33 hours. This model described the formation of intracellular TFV-DP/FTC-TP and the interaction with dNTPs, and can be used to simulate analog:dNTP time course for various dosing strategies.The coformulation of the nucleos(t)ide analogs (NA) tenofovir (TFV) disoproxil fumarate (TDF) and emtricitabine (FTC) is approved for HIV-infection treatment and prevention. Plasma TFV and FTC undergo complicated hybrid processes to form, accumulate, and retain as their active intracellular anabolites: TFV-diphosphate (TFV-DP) and FTC-triphosphate (FTC-TP). Such complexities manifest in nonlinear intracellular pharmacokinetics (PK). In target cells, TFV-DP/FTC-TP compete with endogenous deoxynucleoside triphosphates (dNTP) at the active site of HIV reverse transcriptase, underscoring the importance of analog:dNTP ratios for antiviral efficacy. However, NA such as TFV and FTC have the potential to disturb the dNTP pool, which could augment or reduce their efficacies. We conducted a pharmacokinetics-pharmacodynamics (PKPD) study among forty subjects receiving daily TDF/FTC (300 mg/200 mg) from the first-dose to pharmacological intracellular steady-state (30 days). TFV/FTC in plasma, TFV-DP/FTC-TP and dNTPs in peripheral blood mononuclear cells (PBMC) were quantified using validated LC/MS/MS methodologies. Concentration-time data were analyzed using nonlinear mixed effects modeling (NONMEM). Formations and the accumulation of intracellular TFV-DP/FTC-TP was driven by plasma TFV/FTC, which was described by a hybrid of first-order formation and saturation. An indirect response link model described the interplay between TFV-DP/FTC-TP and the dNTP pool change. The EC50 (interindividual variability, (%CV)) of TFV-DP and FTC-TP on the inhibition of deoxyadenosine triphosphate (dATP) and deoxycytidine triphosphate (dCTP) production were 1020 fmol/106 cells (130%) and 44.4 pmol/106 cells (82.5%), resulting in (90% prediction interval) 11% (0.45%, 53%) and 14% (2.6%, 35%) reductions. Model simulations of analog:dNTP molar ratios using IPERGAY dosing suggested that FTC significantly contributes to the protective effect of preexposure prophylaxis (PrEP). Simulation-based intracellular operational multiple dosing half-lives of TFV-DP and FTC-TP were 6.7 days and 33 hours. This model described the formation of intracellular TFV-DP/FTC-TP and the interaction with dNTPs, and can be used to simulate analog:dNTP time course for various dosing strategies. The coformulation of the nucleos(t)ide analogs (NA) tenofovir (TFV) disoproxil fumarate (TDF) and emtricitabine (FTC) is approved for HIV-infection treatment and prevention. Plasma TFV and FTC undergo complicated hybrid processes to form, accumulate, and retain as their active intracellular anabolites: TFV-diphosphate (TFV-DP) and FTC-triphosphate (FTC-TP). Such complexities manifest in nonlinear intracellular pharmacokinetics (PK). In target cells, TFV-DP/FTC-TP compete with endogenous deoxynucleoside triphosphates (dNTP) at the active site of HIV reverse transcriptase, underscoring the importance of analog:dNTP ratios for antiviral efficacy. However, NA such as TFV and FTC have the potential to disturb the dNTP pool, which could augment or reduce their efficacies. We conducted a pharmacokinetics-pharmacodynamics (PKPD) study among forty subjects receiving daily TDF/FTC (300 mg/200 mg) from the first-dose to pharmacological intracellular steady-state (30 days). TFV/FTC in plasma, TFV-DP/FTC-TP and dNTPs in peripheral blood mononuclear cells (PBMC) were quantified using validated LC/MS/MS methodologies. Concentration-time data were analyzed using nonlinear mixed effects modeling (NONMEM). Formations and the accumulation of intracellular TFV-DP/FTC-TP was driven by plasma TFV/FTC, which was described by a hybrid of first-order formation and saturation. An indirect response link model described the interplay between TFV-DP/FTC-TP and the dNTP pool change. The EC.sub.50 (interindividual variability, (%CV)) of TFV-DP and FTC-TP on the inhibition of deoxyadenosine triphosphate (dATP) and deoxycytidine triphosphate (dCTP) production were 1020 fmol/10.sup.6 cells (130%) and 44.4 pmol/10.sup.6 cells (82.5%), resulting in (90% prediction interval) 11% (0.45%, 53%) and 14% (2.6%, 35%) reductions. Model simulations of analog:dNTP molar ratios using IPERGAY dosing suggested that FTC significantly contributes to the protective effect of preexposure prophylaxis (PrEP). Simulation-based intracellular operational multiple dosing half-lives of TFV-DP and FTC-TP were 6.7 days and 33 hours. This model described the formation of intracellular TFV-DP/FTC-TP and the interaction with dNTPs, and can be used to simulate analog:dNTP time course for various dosing strategies. The coformulation of the nucleos(t)ide analogs (NA) tenofovir (TFV) disoproxil fumarate (TDF) and emtricitabine (FTC) is approved for HIV-infection treatment and prevention. Plasma TFV and FTC undergo complicated hybrid processes to form, accumulate, and retain as their active intracellular anabolites: TFV-diphosphate (TFV-DP) and FTC-triphosphate (FTC-TP). Such complexities manifest in nonlinear intracellular pharmacokinetics (PK). In target cells, TFV-DP/FTC-TP compete with endogenous deoxynucleoside triphosphates (dNTP) at the active site of HIV reverse transcriptase, underscoring the importance of analog:dNTP ratios for antiviral efficacy. However, NA such as TFV and FTC have the potential to disturb the dNTP pool, which could augment or reduce their efficacies. We conducted a pharmacokinetics-pharmacodynamics (PKPD) study among forty subjects receiving daily TDF/FTC (300 mg/200 mg) from the first-dose to pharmacological intracellular steady-state (30 days). TFV/FTC in plasma, TFV-DP/FTC-TP and dNTPs in peripheral blood mononuclear cells (PBMC) were quantified using validated LC/MS/MS methodologies. Concentration-time data were analyzed using nonlinear mixed effects modeling (NONMEM). Formations and the accumulation of intracellular TFV-DP/FTC-TP was driven by plasma TFV/FTC, which was described by a hybrid of first-order formation and saturation. An indirect response link model described the interplay between TFV-DP/FTC-TP and the dNTP pool change. The EC 50 (interindividual variability, (%CV)) of TFV-DP and FTC-TP on the inhibition of deoxyadenosine triphosphate (dATP) and deoxycytidine triphosphate (dCTP) production were 1020 fmol/10 6 cells (130%) and 44.4 pmol/10 6 cells (82.5%), resulting in (90% prediction interval) 11% (0.45%, 53%) and 14% (2.6%, 35%) reductions. Model simulations of analog:dNTP molar ratios using IPERGAY dosing suggested that FTC significantly contributes to the protective effect of preexposure prophylaxis (PrEP). Simulation-based intracellular operational multiple dosing half-lives of TFV-DP and FTC-TP were 6.7 days and 33 hours. This model described the formation of intracellular TFV-DP/FTC-TP and the interaction with dNTPs, and can be used to simulate analog:dNTP time course for various dosing strategies. |
| Audience | Academic |
| Author | MaWhinney, Samantha Seifert, Sharon M. Kiser, Jennifer J. Bushman, Lane R. Chen, Xinhui Castillo-Mancilla, Jose R. Anderson, Peter L. Zheng, Jia-Hua |
| AuthorAffiliation | 3 University of Colorado, Colorado School of Public Health, Department of Biostatistics and Informatics, Aurora, CO, United States of America 1 University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, United States of America Imperial College London, UNITED KINGDOM 2 University of Colorado, School of Medicine, Division of Infectious Diseases, Aurora, CO, United States of America |
| AuthorAffiliation_xml | – name: 2 University of Colorado, School of Medicine, Division of Infectious Diseases, Aurora, CO, United States of America – name: Imperial College London, UNITED KINGDOM – name: 3 University of Colorado, Colorado School of Public Health, Department of Biostatistics and Informatics, Aurora, CO, United States of America – name: 1 University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, United States of America |
| Author_xml | – sequence: 1 givenname: Xinhui orcidid: 0000-0001-5022-3323 surname: Chen fullname: Chen, Xinhui – sequence: 2 givenname: Sharon M. orcidid: 0000-0001-5092-7910 surname: Seifert fullname: Seifert, Sharon M. – sequence: 3 givenname: Jose R. surname: Castillo-Mancilla fullname: Castillo-Mancilla, Jose R. – sequence: 4 givenname: Lane R. surname: Bushman fullname: Bushman, Lane R. – sequence: 5 givenname: Jia-Hua surname: Zheng fullname: Zheng, Jia-Hua – sequence: 6 givenname: Jennifer J. surname: Kiser fullname: Kiser, Jennifer J. – sequence: 7 givenname: Samantha surname: MaWhinney fullname: MaWhinney, Samantha – sequence: 8 givenname: Peter L. surname: Anderson fullname: Anderson, Peter L. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27832147$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk91u1DAQhSNURH_gDRBEQkJwsVs7tuOEC6SqFFhpUREs3FqOY29cHHuxk9K-PQ6bVpuqQlUuHI2_M2OfGR8me9ZZmSTPIZhDROHxheu95Wa-ieE5gDkhgDxKDmCJslmeAbS387-fHIZwAQBBRZ4_SfYzWqAMYnqQ8C-uliZdavtL23X61fDQ8pTbOl3YznMhjekN9-lKWqfcpfbHZ23ntdAdr7SV6R_dNekH6a6ubS-MdEHXMl15vWlc2DS8k-Fp8lhxE-SzcT1Kfnw8W51-ni3PPy1OT5YzQTPSzURcFCpxSUANFSKqEphXpARcQFHykiCYAYVwKUsqC1woIWnUyLyAOcZUoaPk5TbvxrjARncCgwUqsiilJBKLLVE7fsE2XrfcXzPHNfsXcH7NuO90vAbjVSUgIKUidY4zWsZz1UUWbctoTQshYq73Y7W-amUt5OCWmSSd7ljdsLW7ZAQCjFAZE7wZE3j3u5ehY60Og93cStcP58axcmxS9gAUlRBSCGFEX91B7zdipNY83lVb5YZWD0nZCaaxMonjEan5PVT8atlqEadO6RifCN5OBJHp5FW35n0IbPH928PZ859T9vUO20huuiY403fa2TAFX-w25bYbN-MeAbwFhHcheKluEQjY8Kpu7GLDq2Ljq4qyd3dkw_wP5aMj2vxf_BdEkifT |
| CitedBy_id | crossref_primary_10_1111_bcp_15310 crossref_primary_10_1002_cpt_1227 crossref_primary_10_1128_AAC_00207_17 crossref_primary_10_1097_QAD_0000000000002169 crossref_primary_10_1002_cpt_1714 crossref_primary_10_1128_aac_02339_18 crossref_primary_10_4155_bio_2018_0078 crossref_primary_10_1089_aid_2020_0108 crossref_primary_10_1124_jpet_118_251009 |
| Cites_doi | 10.1021/js9901155 10.1007/s10928-008-9088-2 10.1097/QAI.0b013e318050d88c 10.1517/17425255.2012.714367 10.1128/AAC.00910-10 10.1128/AAC.40.1.22 10.1056/NEJMoa1506273 10.1111/j.1468-1293.2004.00194.x 10.1128/AAC.02058-13 10.1089/aid.2004.20.1173 10.1371/journal.pone.0078814 10.1023/A:1012299115260 10.1093/cid/civ346 10.1016/S0169-2607(98)00067-4 10.2165/00003088-200443090-00003 10.2165/00003495-200363150-00006 10.1128/AAC.49.8.3361-3366.2005 10.1007/s10928-008-9094-4 10.2165/11203800-000000000-00000 10.1016/j.ejps.2012.11.007 10.1128/AAC.50.4.1304-1310.2006 10.1007/s11095-008-9787-9 10.1093/jac/dkq447 10.1126/scitranslmed.3004006 10.1016/j.jchromb.2009.05.029 10.1592/phco.21.1.11.34439 10.1097/01.qai.0000167155.44980.e8 10.1016/j.ejps.2008.12.010 10.1371/journal.pone.0040382 10.1023/B:JOPA.0000012999.36063.4e 10.1046/j.1365-2125.1998.00676.x 10.1128/AAC.42.9.2380 10.1126/scitranslmed.3003174 10.1111/bcp.12451 10.1177/135965350601100302 10.1177/135965350801300608 10.1128/AAC.45.10.2733-2739.2001 10.2174/0929867311320340005 10.1128/AAC.01441-15 10.1007/BF02353781 10.1074/jbc.271.14.7887 10.1097/QAD.0b013e32833676eb 10.1128/AAC.05317-11 10.1128/AAC.01517-15 10.1177/0091270007300951 10.1023/B:JOPA.0000012998.04442.1f 10.1128/AAC.49.2.680-684.2005 10.1089/aid.2012.0089 10.1128/AAC.49.5.1907-1914.2005 10.1016/S0022-3565(25)24269-0 10.1038/clpt.2008.201 10.1016/S1567-5769(03)00076-6 10.1002/jcph.461 10.1097/QAD.0b013e32835a9a2d 10.1097/QAI.0b013e3182829bd0 10.1128/AAC.06337-11 10.1128/AAC.48.4.1089-1095.2004 10.1016/j.jpba.2011.05.039 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2016 Public Library of Science 2016 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2016 Chen et al 2016 Chen et al |
| Copyright_xml | – notice: COPYRIGHT 2016 Public Library of Science – notice: 2016 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2016 Chen et al 2016 Chen et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0165505 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection Proquest Central ProQuest Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection ProQuest Biological Science Collection Agriculture Science Database Health & Medical Collection (Alumni) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Engineering Research Database Agricultural Science Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Linking TFV/FTC with dNTPs |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1838212075 oai_doaj_org_article_abbc1059f5d64279949d8227827d78cc PMC5104339 4246116561 A471845832 27832147 10_1371_journal_pone_0165505 |
| Genre | Journal Article Observational Study |
| GeographicLocations | United States--US Colorado |
| GeographicLocations_xml | – name: Colorado – name: United States--US |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: K23 AI104315 – fundername: NCATS NIH HHS grantid: TL1 TR001081 – fundername: NCATS NIH HHS grantid: UL1 TR001082 – fundername: NIAID NIH HHS grantid: U01 AI106499 – fundername: NIAID NIH HHS grantid: U01 AI084735 – fundername: NIAID NIH HHS grantid: T32 AI007447 – fundername: ; grantid: U01 AI106499 – fundername: ; grantid: U01 AI84735 – fundername: ; grantid: UL1 TR001082 – fundername: ; grantid: T32 AI 7447-23 – fundername: ; grantid: TL1 TR001081 |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM BBORY CGR CUY CVF ECM EIF IPNFZ NPM RIG PMFND 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS RC3 7X8 5PM PUEGO - 02 AAPBV ABPTK ADACO BBAFP KM |
| ID | FETCH-LOGICAL-c725t-cc72f394950d1f35fbc4ab590ac1c9a953120f349e97e848fce7cc7e6816447f3 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Fri Nov 26 17:13:35 EST 2021 Wed Aug 27 01:05:44 EDT 2025 Thu Aug 21 18:18:58 EDT 2025 Tue Aug 05 10:56:34 EDT 2025 Fri Jul 11 00:47:06 EDT 2025 Fri Jul 25 11:30:32 EDT 2025 Tue Jun 17 20:49:27 EDT 2025 Tue Jun 10 20:49:45 EDT 2025 Fri Jun 27 04:43:11 EDT 2025 Fri Jun 27 04:59:22 EDT 2025 Thu May 22 21:31:19 EDT 2025 Thu Apr 03 07:05:19 EDT 2025 Thu Jul 03 08:24:44 EDT 2025 Thu Apr 24 22:55:58 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c725t-cc72f394950d1f35fbc4ab590ac1c9a953120f349e97e848fce7cc7e6816447f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 Competing Interests: Peter Anderson’s institution received study drug donation and research grants from Gilead Sciences. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Conceptualization: XC PLA JJK SM. Data curation: LRB XC SMS PLA. Formal analysis: XC SM SMS PLA. Funding acquisition: PLA SMS XC. Investigation: XC SMS JRCM LRB JHZ JJK SM PLA. Methodology: XC LRB JHZ XC SM PLA. Project administration: PLA LRB. Resources: PLA JJK. Supervision: SM LRB JJK PLA. Validation: XC SM PLA LRB. Visualization: XC SM PLA. Writing – original draft: XC PLA SM. Writing – review & editing: XC SMS JRCM LRB JHZ JJK SM PLA. |
| ORCID | 0000-0001-5022-3323 0000-0001-5092-7910 |
| OpenAccessLink | https://doaj.org/article/abbc1059f5d64279949d8227827d78cc |
| PMID | 27832147 |
| PQID | 1838212075 |
| PQPubID | 1436336 |
| PageCount | e0165505 |
| ParticipantIDs | plos_journals_1838212075 doaj_primary_oai_doaj_org_article_abbc1059f5d64279949d8227827d78cc pubmedcentral_primary_oai_pubmedcentral_nih_gov_5104339 proquest_miscellaneous_1846422142 proquest_miscellaneous_1839117111 proquest_journals_1838212075 gale_infotracmisc_A471845832 gale_infotracacademiconefile_A471845832 gale_incontextgauss_ISR_A471845832 gale_incontextgauss_IOV_A471845832 gale_healthsolutions_A471845832 pubmed_primary_27832147 crossref_primary_10_1371_journal_pone_0165505 crossref_citationtrail_10_1371_journal_pone_0165505 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-11-10 |
| PublicationDateYYYYMMDD | 2016-11-10 |
| PublicationDate_xml | – month: 11 year: 2016 text: 2016-11-10 day: 10 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2016 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | T Hawkins (ref21) 2005; 39 JM Molina (ref54) 2004; 5 T Chapman (ref1) 2003; 63 TR Cressey (ref17) 2015; 61 N Biswas (ref26) 2013; 8 T Delahunty (ref35) 2009; 877 SM Seifert (ref22) 2016 JR Castillo-Mancilla (ref60) 2013; 29 G Baheti (ref8) 2013; 27 K Borroto-Esoda (ref48) 2006; 11 AC Skladanowski (ref52) 2013; 20 S Ramanathan (ref56) 2007; 45 JM Molina (ref33) 2015; 373 T Hawkins (ref20) 2011; 55 JE Rower (ref53) 2012; 56 BP Kearney (ref2) 2004; 43 S Bantia (ref29) 2003; 3 M Goicoechea (ref19) 2010; 24 YN Sun (ref44) 1999; 88 G Baheti (ref7) 2011; 55 E Valade (ref14) 2014; 58 L Zhang (ref39) 2003; 30 PL Anderson (ref16) 2012; 4 A Jackson (ref12) 2013; 62 JE Vela (ref27) 2008; 13 K Madrasi (ref5); 3 DS Stein (ref49) 2001; 21 ED Deeks (ref55) 2010; 70 MM Hutmacher (ref46) 2015; 79 L Dickinson (ref18) 2015; 59 PL Anderson (ref50) 2011; 66 LH Wang (ref59) 2004; 20 ML Cottrell (ref31) 2016 A Uglietti (ref13) 2012; 8 M von Kleist (ref23) 2009; 36 P Barditch-Crovo (ref9) 2001; 45 WJ Jusko (ref42) 1995; 23 JA Droste (ref10) 2005; 49 MR Blum (ref58) 2007; 47 C Dansirikul (ref45) 2008; 35 V Jullien (ref25) 2005; 49 EN Jonsson (ref47) 1999; 58 JE Ahn (ref37) 2008; 35 S Sahin (ref32) 2008; 25 KB Patterson (ref63) 2011; 3 S Duwal (ref6) 2012; 7 X Chen (ref30) 2016 LR Bushman (ref34) 2011; 56 RN Burns (ref24) 2015; 55 SL Beal (ref38) 2001; 28 A Pruvost (ref62) 2005; 49 X Chen (ref36) 2016 A Varga (ref4) 2013; 48 L Naesens (ref3) 1996; 40 E Valade (ref15) 2015; 59 SG Deeks (ref61) 1998; 42 D Hirt (ref11) 2009; 85 L Zhang (ref40) 2003; 30 J Bourdais (ref51) 1996; 271 HC Porchet (ref41) 1988; 244 GE Chittick (ref57) 2006; 50 AS Ray (ref28) 2004; 48 A Sharma (ref43) 1998; 45 |
| References_xml | – volume: 3 start-page: e147 ident: ref5 article-title: Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism publication-title: CPT: pharmacometrics & systems pharmacology – volume: 88 start-page: 987 issue: 10 year: 1999 ident: ref44 article-title: Role of baseline parameters in determining indirect pharmacodynamic responses publication-title: J Pharm Sci doi: 10.1021/js9901155 – volume: 35 start-page: 269 issue: 3 year: 2008 ident: ref45 article-title: Approaches to handling pharmacodynamic baseline responses publication-title: J Pharmacokinet Pharmacodyn doi: 10.1007/s10928-008-9088-2 – volume: 45 start-page: 274 issue: 3 year: 2007 ident: ref56 article-title: Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e318050d88c – volume: 8 start-page: 1305 issue: 10 year: 2012 ident: ref13 article-title: Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation publication-title: Expert Opin Drug Metab Toxicol doi: 10.1517/17425255.2012.714367 – volume: 55 start-page: 1549 issue: 4 year: 2011 ident: ref20 article-title: Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00910-10 – volume: 40 start-page: 22 issue: 1 year: 1996 ident: ref3 article-title: Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.40.1.22 – volume: 373 start-page: 2237 issue: 23 year: 2015 ident: ref33 article-title: On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection publication-title: N Engl J Med doi: 10.1056/NEJMoa1506273 – volume: 5 start-page: 99 issue: 2 year: 2004 ident: ref54 article-title: Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial) publication-title: HIV medicine doi: 10.1111/j.1468-1293.2004.00194.x – volume: 58 start-page: 2256 issue: 4 year: 2014 ident: ref14 article-title: Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02058-13 – volume: 20 start-page: 1173 issue: 11 year: 2004 ident: ref59 article-title: Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection publication-title: AIDS Res Hum Retroviruses doi: 10.1089/aid.2004.20.1173 – volume: 8 start-page: e78814 issue: 10 year: 2013 ident: ref26 article-title: Effect of tenofovir on nucleotidases and cytokines in HIV-1 target cells publication-title: PLoS One doi: 10.1371/journal.pone.0078814 – volume: 28 start-page: 481 issue: 5 year: 2001 ident: ref38 article-title: Ways to fit a PK model with some data below the quantification limit publication-title: J Pharmacokinet Pharmacodyn doi: 10.1023/A:1012299115260 – volume: 61 start-page: 633 issue: 4 year: 2015 ident: ref17 article-title: Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment publication-title: Clin Infect Dis doi: 10.1093/cid/civ346 – year: 2016 ident: ref30 article-title: Analysis of the endogenous deoxynucleoside triphosphate pool in HIV positive and negative individuals receiving tenofovir-emtricitabine publication-title: Antimicrob Agents Chemother – volume: 58 start-page: 51 issue: 1 year: 1999 ident: ref47 article-title: Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM publication-title: Computer methods and programs in biomedicine doi: 10.1016/S0169-2607(98)00067-4 – volume: 43 start-page: 595 issue: 9 year: 2004 ident: ref2 article-title: Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics publication-title: Clinical pharmacokinetics doi: 10.2165/00003088-200443090-00003 – volume: 63 start-page: 1597 issue: 15 year: 2003 ident: ref1 article-title: Tenofovir disoproxil fumarate publication-title: Drugs doi: 10.2165/00003495-200363150-00006 – volume: 49 start-page: 3361 issue: 8 year: 2005 ident: ref25 article-title: Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.49.8.3361-3366.2005 – volume: 35 start-page: 401 issue: 4 year: 2008 ident: ref37 article-title: Likelihood based approaches to handling data below the quantification limit using NONMEM VI publication-title: J Pharmacokinet Pharmacodyn doi: 10.1007/s10928-008-9094-4 – volume: 70 start-page: 2315 issue: 17 year: 2010 ident: ref55 article-title: Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla(R)): a review of its use in the management of HIV infection publication-title: Drugs doi: 10.2165/11203800-000000000-00000 – volume: 48 start-page: 307 issue: 1–2 year: 2013 ident: ref4 article-title: Selectivity of kinases on the activation of tenofovir, an anti-HIV agent publication-title: Eur J Pharm Sci doi: 10.1016/j.ejps.2012.11.007 – volume: 50 start-page: 1304 issue: 4 year: 2006 ident: ref57 article-title: Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.50.4.1304-1310.2006 – volume: 25 start-page: 2869 issue: 12 year: 2008 ident: ref32 article-title: The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms publication-title: Pharm Res doi: 10.1007/s11095-008-9787-9 – volume: 66 start-page: 240 issue: 2 year: 2011 ident: ref50 article-title: Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkq447 – volume: 4 start-page: 151ra25 issue: 151 year: 2012 ident: ref16 article-title: Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3004006 – volume: 877 start-page: 1907 issue: 20–21 year: 2009 ident: ref35 article-title: The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards publication-title: J Chromatogr B Analyt Technol Biomed Life Sci doi: 10.1016/j.jchromb.2009.05.029 – volume: 21 start-page: 11 issue: 1 year: 2001 ident: ref49 article-title: Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians publication-title: Pharmacotherapy doi: 10.1592/phco.21.1.11.34439 – volume: 39 start-page: 406 issue: 4 year: 2005 ident: ref21 article-title: Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens publication-title: J Acquir Immune Defic Syndr doi: 10.1097/01.qai.0000167155.44980.e8 – volume: 36 start-page: 532 issue: 4–5 year: 2009 ident: ref23 article-title: Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: an example based on zidovudine publication-title: Eur J Pharm Sci doi: 10.1016/j.ejps.2008.12.010 – volume: 7 start-page: e40382 issue: 7 year: 2012 ident: ref6 article-title: Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection publication-title: PLoS One doi: 10.1371/journal.pone.0040382 – volume: 30 start-page: 405 issue: 6 year: 2003 ident: ref40 article-title: Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods publication-title: J Pharmacokinet Pharmacodyn doi: 10.1023/B:JOPA.0000012999.36063.4e – volume: 45 start-page: 229 issue: 3 year: 1998 ident: ref43 article-title: Characteristics of indirect pharmacodynamic models and applications to clinical drug responses publication-title: Br J Clin Pharmacol doi: 10.1046/j.1365-2125.1998.00676.x – volume: 42 start-page: 2380 issue: 9 year: 1998 ident: ref61 article-title: Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.42.9.2380 – volume: 3 start-page: 112re4 issue: 112 year: 2011 ident: ref63 article-title: Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3003174 – volume: 79 start-page: 132 issue: 1 year: 2015 ident: ref46 article-title: Covariate selection in pharmacometric analyses: a review of methods publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.12451 – volume: 11 start-page: 377 issue: 3 year: 2006 ident: ref48 article-title: In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine publication-title: Antivir Ther doi: 10.1177/135965350601100302 – volume: 13 start-page: 789 issue: 6 year: 2008 ident: ref27 article-title: Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools publication-title: Antivir Ther doi: 10.1177/135965350801300608 – volume: 45 start-page: 2733 issue: 10 year: 2001 ident: ref9 article-title: Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.45.10.2733-2739.2001 – volume: 20 start-page: 4249 issue: 34 year: 2013 ident: ref52 article-title: The role of soluble 5'-nucleotidases in the conversion of nucleotide analogs: metabolic and therapeutic aspects publication-title: Current medicinal chemistry doi: 10.2174/0929867311320340005 – volume: 59 start-page: 6080 issue: 10 year: 2015 ident: ref18 article-title: Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01441-15 – start-page: 27526873 year: 2016 ident: ref22 article-title: Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State publication-title: AIDS Res Hum Retroviruses – volume: 23 start-page: 5 issue: 1 year: 1995 ident: ref42 article-title: Convergence of direct and indirect pharmacodynamic response models publication-title: J Pharmacokinet Biopharm doi: 10.1007/BF02353781 – volume: 271 start-page: 7887 issue: 14 year: 1996 ident: ref51 article-title: Cellular phosphorylation of anti-HIV nucleosides. Role of nucleoside diphosphate kinase publication-title: J Biol Chem doi: 10.1074/jbc.271.14.7887 – volume: 24 start-page: 707 issue: 5 year: 2010 ident: ref19 article-title: Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients publication-title: AIDS doi: 10.1097/QAD.0b013e32833676eb – volume: 55 start-page: 5294 issue: 11 year: 2011 ident: ref7 article-title: Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.05317-11 – volume: 59 start-page: 6800 issue: 11 year: 2015 ident: ref15 article-title: Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men in the EVARIST ANRS-EP 49 study publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01517-15 – volume: 47 start-page: 751 issue: 6 year: 2007 ident: ref58 article-title: Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers publication-title: J Clin Pharmacol doi: 10.1177/0091270007300951 – volume: 30 start-page: 387 issue: 6 year: 2003 ident: ref39 article-title: Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance publication-title: J Pharmacokinet Pharmacodyn doi: 10.1023/B:JOPA.0000012998.04442.1f – volume: 49 start-page: 680 issue: 2 year: 2005 ident: ref10 article-title: Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.49.2.680-684.2005 – volume: 29 start-page: 384 issue: 2 year: 2013 ident: ref60 article-title: Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure publication-title: AIDS Res Hum Retroviruses doi: 10.1089/aid.2012.0089 – volume: 49 start-page: 1907 issue: 5 year: 2005 ident: ref62 article-title: Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.49.5.1907-1914.2005 – year: 2016 ident: ref36 article-title: Development and validation of an LC-MS/MS quantitative method for endogenous deoxynucleoside triphosphates in cellular lysate publication-title: Biomed Chromatogr – volume: 244 start-page: 231 issue: 1 year: 1988 ident: ref41 article-title: Pharmacodynamic model of tolerance: application to nicotine publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(25)24269-0 – volume: 85 start-page: 182 issue: 2 year: 2009 ident: ref11 article-title: Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109) publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2008.201 – volume: 3 start-page: 879 issue: 6 year: 2003 ident: ref29 article-title: Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor—BCX-1777 publication-title: International immunopharmacology doi: 10.1016/S1567-5769(03)00076-6 – volume: 55 start-page: 629 issue: 6 year: 2015 ident: ref24 article-title: Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women publication-title: J Clin Pharmacol doi: 10.1002/jcph.461 – volume: 27 start-page: 221 issue: 2 year: 2013 ident: ref8 article-title: Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults publication-title: AIDS doi: 10.1097/QAD.0b013e32835a9a2d – volume: 62 start-page: 275 issue: 3 year: 2013 ident: ref12 article-title: Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3182829bd0 – volume: 56 start-page: 3011 issue: 6 year: 2012 ident: ref53 article-title: Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.06337-11 – volume: 48 start-page: 1089 issue: 4 year: 2004 ident: ref28 article-title: Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.48.4.1089-1095.2004 – year: 2016 ident: ref31 article-title: A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine publication-title: J Infect Dis – volume: 56 start-page: 390 issue: 2 year: 2011 ident: ref34 article-title: Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection publication-title: J Pharm Biomed Anal doi: 10.1016/j.jpba.2011.05.039 |
| SSID | ssj0053866 |
| Score | 2.2643492 |
| Snippet | The coformulation of the nucleos(t)ide analogs (NA) tenofovir (TFV) disoproxil fumarate (TDF) and emtricitabine (FTC) is approved for HIV-infection treatment... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0165505 |
| SubjectTerms | Acquired immune deficiency syndrome Adult AIDS Analogs Analysis Anti-HIV Agents - blood Anti-HIV Agents - metabolism Anti-HIV Agents - pharmacokinetics Anti-HIV Agents - pharmacology Antiretroviral agents Antiretroviral drugs Biology and Life Sciences Computer Simulation Data processing Deoxyadenine Nucleotides - metabolism Deoxyadenosine Deoxycytosine Nucleotides - metabolism Diphosphates - metabolism Disease prevention DNA polymerases Dosage Drug dosages Emtricitabine Emtricitabine - blood Emtricitabine - metabolism Emtricitabine - pharmacokinetics Emtricitabine - pharmacology Female Health aspects HIV HIV - drug effects HIV Infections - drug therapy Human immunodeficiency virus Humans Infections Intracellular Lentivirus Leukocytes (mononuclear) Male Medicine and Health Sciences Metabolism Metabolites Middle Aged Models, Biological Nonlinear analysis Peripheral blood mononuclear cells Pharmaceutical sciences Pharmacodynamics Pharmacokinetics Pharmacology Pharmacy Plasma Polyphosphates - metabolism Prophylaxis Prospective Studies Research and Analysis Methods Retroviridae RNA-directed DNA polymerase Simulation Tenofovir Tenofovir - blood Tenofovir - metabolism Tenofovir - pharmacokinetics Tenofovir - pharmacology Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELdQn_aCGBssbICHkICHbPlwYvtx7EMb4kvQob1ZjmPTSl1SLS2C_567xI0aNDEeeGpUn9Pmzvdh5-53hLwsSpcbJ-MwkVqErISrwkVFmBpmTMpj7RKsd_7wMT-_ZO-usqu1Vl-YE9bBA3eMw5ZaBmMAl5UQKnMpmSwF1m8mvOTCGLS-4PNWm6nOBoMW57kvlIMfPPRyOZjXlT3AAp4M29WtOaIWr7-3yqP5rG5uCzn_zJxcc0VnD8h9H0PSo-6_b5J7tnpINr2WNvS1h5J-s0U0tjqb0fddgwT6GULla011VdILvDOe2mMaKh3bqnb1j-nN4ek1QvZPFxp2zJbiKS09sfXPXxXiHtfY25OOwc5M6mY-wTB1m1yenY6Pz0PfVCE0PMkWoYEPlwIXs6iMXZq5wjBdZDLSJjZSS9DJJHIpk1ZyK5hwxnKYY3MBGyvGXfqIjCpg4w6hELoIGTFXlLHBM0nBNJOMs4xHuS1YHpB0xWFlPOI4Nr6YqfY1GoedR8cwhXJRXi4BCftZ8w5x4w76tyi8nhbxstsvYBUpv4rUXasoIM9R9KorPu21Xh2h78ZXy0lAXrQUiJlRYVLOd71sGnXx6ds_EH39MiB65YlcjaLWvhACngmxuAaUewNK0HwzGN7BhbriSqPAPAsIRSAKhJmrxXv78H4_jDfFRLvK1suWBtwfBw_4NxoGTESsvoA87vSh5z42bsHWVwHhA00ZiGc4Uk0nLaw5eAeWpvLJ_5DnLtmAyDYP23zNPTJa3CztU4geF8Wz1lD8BnXKbeg priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELegvPCCGF8LbGAQEvCQNR9OHD-hAZs2xJegQ32LHMdeK3VxaNoJ_nvuEjcsaBo8taovSXPn893Zd78j5HlRmlQZEfqRkJnPSvhWmKDwY8WUinkoTYT1zh8_pUcn7P00mboNt8alVW7WxHahLq3CPfIxTL0MllmwcK_rHz52jcLTVddC4zq5gdBlmNLFp33ABbqcpq5cDh47dtLZq22l97CMJ8GmdRfMUYva36_No3phm8scz7_zJy8YpMPb5JbzJOl-J_otck1Xd8iW09WGvnSA0q_uEokNzxb0Q9cmgX4Bh_lMUlmV9BjvjHv3mIxKJ7qyxp7Pl-ODMwTun68kxM2a4l4tfaftz18Voh9b7PBJJ7DazGxTz9BZvUdODg8mb49811rBVzxKVr6CDxMLiI6CMjRxYgrFZJGIQKpQCSlAM6PAxExowXXGMqM0h2t0mkF4xbiJ75NRBWzcJhQcmEwEzBRlqHBnMmOSCcZZwoNUFyz1SLzhcK4c7ji2v1jk7WEah_ijY1iOcsmdXDzi91fVHe7GP-jfoPB6WkTNbn-wy9PcKWEui0KhP2mSEsIuLuD9ywxrgSNe8kwpjzxB0eddCWqv-_k-WnA8YI488qylQOSMClNzTuW6afLjz9__g-jb1wHRC0dkLIpaunIIeCdE5BpQ7gwoQf_VYHgbJ-qGK03-R1Pgys3kvXz4aT-MN8V0u0rbdUsDRpCDHbyKhgETEbHPIw86fei5j-1bsAGWR_hAUwbiGY5U81kLbg42gsWxeHj1X39EboLnmvptPuYOGa2Wa70L3uGqeNwuAb8BoFll2w priority: 102 providerName: ProQuest |
| Title | Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27832147 https://www.proquest.com/docview/1838212075 https://www.proquest.com/docview/1839117111 https://www.proquest.com/docview/1846422142 https://pubmed.ncbi.nlm.nih.gov/PMC5104339 https://doaj.org/article/abbc1059f5d64279949d8227827d78cc http://dx.doi.org/10.1371/journal.pone.0165505 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdG98ILYnwtMEpASMBDSj6cOH5AaBstG2JjGi3qW-Q49lqpS0rTou2Fv507J40IKoyXtIrPlnLn893Zvt8R8jLNdCQ19xyfi9ihGfxLtZs6gaRSBswT2sd855PT6GhEP43D8RZZ12ytGVhuDO2wntRoMetdfb9-Dwr_zlRtYN66U29e5KqH6Tkhgppug21iqKontDlXAO02p5fotTiR7wZ1Mt3fRmkZK4Pp36zcnfmsKDe5pX_ervzNXA3ukju1n2nvVxNjh2yp_B7ZqTW5tF_XcNNv7hOB5dBm9ueqiIJ9Bu70pbBFntnHODLu7ONVVXuo8kIXP6aLt_1LhPWfLgVE1crGnVz7gyqurnPERi6w_qc9hLVoUpTzCbqyD8ho0B8eHjl14QVHMj9cOhJ-dMAhdnIzTwehTiUVachdIT3JBQe99V0dUK44UzGNtVQM-qgohuCLMh08JJ0c2LhLbHBvYu5SnWaexH3LmArKKaMhcyOV0sgiwZrDiaxRybE4xiwxR20MopOKYQnKJanlYhGn6TWvUDluoD9A4TW0iKltXhSLi6RW0USkqURvU4cZBGWMw_dnMWYK-yxjsZQWeYaiT6oE1WZlSPbRvuPxs2-RF4YCcTVyvLhzIVZlmRx_-fYfRF_PW0SvaiJdoKhFnSwB34R4XS3KvRYlrA6y1byLE3XNlTKBJTwGdwU8Rei5nrybm583zTgoXsbLVbEyNGAiGVjJf9FQYCLi-VnkUaUPDfexuAuWx7IIa2lKSzztlnw6MdDnYEFoEPDHN4riCbkNrm3kmAube6SzXKzUU3Afl2mX3GJjBs_40MPn4GOXbB_0T8_Ou2ZDpmtWDHz-7P8CL0N1BA |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1db9Mw0BrlAV4Q42uBwQwCAQ9Z08SJ4weEBtu0sm4g6Ka-Bcex10pdUpoW2J_iN3KXLxY0DV721Ko-W_Xd-T7s-yDkeZyYQBnRs10hQ5sl8C02Tmx7iinl8Z40LuY7HxwGe0fsw8gfrZBfdS4MhlXWMrEQ1Emm8I68C6wXgpgFDfd29s3GrlH4ulq30CjZYl-f_QCXLX_T3wb6vnDd3Z3h-z276ipgK-76C1vBh_EEOAZO0jOeb2LFZOwLR6qeElIAU7qO8ZjQguuQhUZpDnN0EIJnwbjxYN1r5DooXgdPFB81Dh7IjiCo0vNgm92KGzZnWao3MW3IxyZ559Rf0SWg0QWd2TTLLzJ0_47XPKcAd2-TW5XlSrdKVlslKzq9Q1Yr2ZDTV1UB69d3icQGa1M6KNsy0E9goJ9KKtOE9nFlfCvA4Fc61Glmsu-TeXfnFBsFTBYS_HRN8W6Ybuvs51mK1ZYz7ChKhyDdxlk-G6NxfI8cXQnS75NOCmhcIxQMplA4zMRJT-FNaMgkE4wznzuBjllgEa_GcKSqOufYbmMaFY93HPydEmER0iWq6GIRu5k1K-t8_AP-HRKvgcUq3cUP2fwkqg59JONYof1q_ATcPC5g_0mIuccuT3iolEU2kPRRmfLayJpoCy0GfNB2LfKsgMBKHSmGAp3IZZ5H_Y_H_wH05XML6GUFZDIktazSL2BPWAGsBbneggR5o1rDa8ioNVby6M_JhJk18148_LQZxkUxvC_V2bKAAaXLQe9eBsMAiVgh0CIPyvPQYB_bxWDDLYvw1klpkac9kk7GRTF10EnM88TDy__6BrmxNzwYRIP-4f4jchOs5sAuYkHXSWcxX-rHYJku4ieFOKDk61XLn99fIKK2 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1db9Mw0BpFQrwgxtcCgwUEAh6y5sOJ4weEBt20sjEm6Ka-Bcex10pdUpoW2F_j13GXuGFB0-BlT63qs1Xfne_Dvg9CnqeZjqTmnuNzETs0g2-pdlMnkFTKgHlC-5jv_PEg2j2iH4bhcIX8WubCYFjlUiZWgjorJN6Rd4H1YhCzoOG62oRFHPZ23k6_OdhBCl9al-00ahbZU2c_wH0r3_R7QOsXvr-zPXi_65gOA45kfjh3JHzogIOT4GaeDkKdSirSkLtCepILDgzquzqgXHGmYhprqRjMUVEMXgZlOoB1r5HrLAg9PGNs2Dh7IEeiyKTqwZa7hjM2p0WuNjGFKMSGeedUYdUxoNELnemkKC8yev-O3TynDHduk1vGirW3arZbJSsqv0NWjZwo7VemmPXru0Rgs7WJvV-3aLAPwVg_FbbIM7uPK-O7AQbC2gOVF7r4Pp51t0-xacB4LsBnVzbeE9s9Vfw8y7HycoHdRe0BSLpRUU5HaCjfI0dXgvT7pJMDGteIDcZTzF2q08yTeCsaU0E5ZTRkbqRSGlkkWGI4kabmObbemCTVQx4D36dGWIJ0SQxdLOI0s6Z1zY9_wL9D4jWwWLG7-qGYnSRGACQiTSXasjrMwOVjHPafxZiH7LOMxVJaZANJn9Tpr43cSbbQesDHbd8izyoIrNqRI_-fiEVZJv1Px_8B9OVzC-ilAdIFklqYVAzYE1YDa0GutyBB9sjW8Boy6hIrZfLnlMLMJfNePPy0GcZFMdQvV8WiggEFzEAHXwZDAYlYLdAiD-rz0GAfW8dg8y2LsNZJaZGnPZKPR1VhddBPNAj4w8v_-ga5AZIn2e8f7D0iN8GAjpwqLHSddOazhXoMRuo8fVJJA5t8vWrx8xsFsabs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Model+Linking+Plasma+and+Intracellular+Tenofovir%2FEmtricitabine+with+Deoxynucleoside+Triphosphates&rft.jtitle=PloS+one&rft.au=Zheng%2C+Jia-Hua&rft.au=Kiser%2C+Jennifer+J&rft.au=MaWhinney%2C+Samantha&rft.au=Anderson%2C+Peter+L&rft.date=2016-11-10&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=11&rft.issue=11&rft.spage=e0165505&rft_id=info:doi/10.1371%2Fjournal.pone.0165505&rft.externalDBID=n%2Fa&rft.externalDocID=A471845832 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |